Abstract: SA-PO0630
Efficacy and Safety of Finerenone in Adults with IgAN: A 12-Month Real-World Study
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Pei, Juan, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
- Shao, Leping, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
- Li, Yinan, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of end-stage renal disease. Finerenone reduces proteinuria in diabetic kidney disease, but evidence in IgAN remains limited.
Methods
This single-center retrospective study included adults with biopsy-proven IgAN who initiated finerenone therapy between January 2023 and December 2025 and were followed for at least 90 days. The primary outcomes included changes in 24-hour urinary protein (24hUP) and estimated glomerular filtration rate (eGFR), and subgroup analysis was performed in patients not receiving immunosuppressive therapy.
Results
A total of 52 patients were included (mean age 40.6±9.7 years; 71.2% female). Median 24hUP decreased from 750.0 mg/24h at baseline to 496.0 mg/24h at Month 12 (median reduction 29.7%, p=0.003), with significant reduction observed from Month 6. Among patients with baseline 24hUP ≥300 mg/24h, complete remission was achieved in 15.6% and partial remission in 15.6% at Month 12. In the non-immunosuppressive subgroup (n=43), significant reduction was also found at Month 12 (p=0.017). eGFR remained stable throughout follow-up (p=0.873). Serum potassium increased slightly but remained clinically manageable, with only 3.8% of patients experiencing transient hyperkalemia (≥5.5 mmol/L), and no treatment discontinuations or serious adverse events occurred.
Conclusion
Finerenone was associated with sustained proteinuria reduction and stable kidney function, with a favorable safety profile over 12 months.
Acknowledgment
We are grateful to all participants, the doctors, and nurses of the Nephrology department for their efforts and contributions to this research.
Figure 1. Changes in proteinuria at baseline and at months 1, 3, 6, 9, and 12.(b) Median change (%) in 24hUP from baseline in patients receiving finerenone.